Held
HUM · Humana Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
Kill line
A daily close below $383 invalidates the renewed continuation thesis at the price boundary retained from the September 11, 2026 dossier; a reduction in the September 1 full-year adjusted EPS floor of $9.00 would separately break the earnings-stability premise.
Pick status
Open commitment catalyst in 18dscored if the kill line above fires How this is scored →Latest analysis and events for HUM —
As of 20 September 2026, the latest FrontierPicks analysis for Humana Inc. (HUM): Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
Kill line: A daily close below $383 invalidates the renewed continuation thesis at the price boundary retained from the September 11, 2026 dossier; a reduction in the September 1 full-year adjusted EPS floor of $9.00 would separately break the earnings-stability premise.
Next dated event on file: — catalyst in 18d.
Current Thesis
Humana's Medicare Advantage margin-recovery story supports a renewed continuation thesis, resolved by an adjusted daily close above $409.80 before a daily close below $383. The September 18, 2026 adjusted close was $386.22, leaving that price test unresolved. Management's September 1 reaffirmation of full-year adjusted earnings per share (EPS) of at least $9.00 supports earnings stability; it does not establish the recovery to management's stated pre-tax Medicare Advantage margin objective of at least 3% in 2028. September filing, July 29 management remarks.
The previous continuation test was met by the September 11, 2026 market close of $409.80; this refresh assesses whether the recovery story can support another high following the retreat. The narrative is maturing — September's earnings reaffirmation extends the existing story, while the September 18 reference close sits below the September 11 close. This is an inference about the narrative's development; a raised company outlook accompanied by an adjusted daily close above $409.80 would contradict it. Historical daily closes.
Bullish and bearish views on Humana Inc.
The model's bull view on Humana Inc. (HUM), in brief: The earnings floor remains intact. Humana reaffirmed full-year adjusted EPS of at least $9.00 on September 1, 2026. A reduction below that floor would invalidate the earnings-stability premise. Form 8-K. Quarterly medical costs met expectations. Humana reported a second-quarter… The bear view: Annual cost pressure remains unresolved. Both cases follow in full.
Bull Case
- The earnings floor remains intact. Humana reaffirmed full-year adjusted EPS of at least $9.00 on September 1, 2026. A reduction below that floor would invalidate the earnings-stability premise. Form 8-K.
- Quarterly medical costs met expectations. Humana reported a second-quarter insurance benefit ratio of 91.2% on July 29, 2026, consistent with management's expectation of slightly above 91%. This ratio measures benefit expense relative to premium revenue; one quarter is too small a sample to establish durable cost improvement. Quarterly results.
- The longer-term objective remains explicit. Management reiterated a pre-tax Medicare Advantage margin objective of at least 3% in 2028 on July 29, 2026. Withdrawal or reduction of that objective would break this component of the recovery case. Management remarks.
Bear Case
- Annual cost pressure remains unresolved. July 29, 2026 guidance put the full-year insurance benefit ratio at 92.75%, plus or minus 25 basis points. An upward revision to that range would contradict the cost-control premise. Quarterly release.
- Quality recovery remains unproven. Management's July 29, 2026 top-quartile Stars objective specified monthly Stars revenue per member 10% above the peer-group median. A disclosed result below that benchmark would miss the objective; publication of new ratings alone would not establish its achievement. Management remarks.
- Price confirmation has not persisted. The supplied September 18, 2026 adjusted series shows a $386.22 close, 5.8% below its $409.80 reference high. The renewed continuation case fails on a daily close below the previously published $383 threshold.
Setup & Price Structure
The September 18, 2026 adjusted series records a three-month price increase of 7.3% and a 14-period relative strength index (RSI) of 50.5. These are measured price observations. They support neither a claim of expanding participation nor a claim of concentrated ownership; no moving-average or ownership-concentration measurement is supplied.
Benzinga's September 2 and September 11, 2026 healthcare options-activity headlines show recurring coverage. Their supplied excerpts do not identify Humana-specific directional exposure, opening transactions or investor identities. The sample is too small to support a crowding claim.
The continuation forecast carries low conviction: the September 18 close remains above the $383 invalidation threshold but below the $409.80 confirmation threshold, while the September 1 earnings floor was reaffirmed rather than raised. A daily close above $409.80 before a daily close below $383 is the observable success condition.
Catalyst Calendar (next 30 days)
- ~2026-10-08, estimated: final 2027 Star Ratings. The Centers for Medicare & Medicaid Services (CMS) confirms October publication in its April 6, 2026 rate announcement; the specific day remains unconfirmed. The ratings test the quality-bonus component of Humana's recovery narrative. A disclosed result below management's July 29 Stars revenue benchmark would contradict that component. CMS publication timetable.
What Would Change Our Mind
Loss of the advance's published price boundary would end the renewed continuation case: a daily close below $383 is the gradeable condition, retained from the September 11, 2026 dossier. The level is a research threshold, not a demonstrated moving average or a newly measured support shelf.
The earnings premise would separately fail if Humana reduced the September 1 adjusted EPS floor of $9.00, raised the July 29 insurance benefit-ratio guidance range, or withdrew the July 29 objective of at least 3% pre-tax Medicare Advantage margin in 2028. An adjusted daily close above $409.80 before invalidation would complete the price case; it would not establish that the operating-margin objective had been achieved.
Correlation Notes
FrontierPicks' September 20, 2026 Managed care & health services review groups Humana with CNC, OSCR and HNGE and describes the cluster as saturated, a classification repeated since August 4. That editorial assessment provides context for attention around the group; it does not measure return correlation or establish Humana-specific crowding. No paired return sample is supplied, so a numerical correlation claim is unsupported.
CMS's April 2, 2026 final-rule fact sheet states that Star Ratings determine quality-bonus payments and affect Medicare Advantage rebates. This supplies a common policy channel for insurers with Medicare Advantage exposure, but it does not establish equivalent exposure across the named theme peers. CMS final-rule fact sheet.
Notes
- Medicare Advantage revenue is set annually by the CMS rate notice and locked at bid; plans cannot reprice intra-year, so a cost miss lands in full on the benefit ratio.
- Star Ratings published each October carry a multi-year lag into quality-bonus revenue, so one weak cycle can impair payments two plan years forward.
- FY2026 guidance has two lines, now both filed: at least $9.00 adjusted EPS and at least $6.52 GAAP, bridged by $2.48 of disclosed adjustments in the 2026-09-01 8-K.
- No 2027 EPS, margin or membership guidance is published. The only forward figure management stands behind is a pre-tax MA margin of at least 3% in 2028, reaffirmed on the 2026-07-29 call.
- The $541.5M DOJ settlement names The Villages Health System LLC, the pre-sale entity in Chapter 11, not Humana. Humana's own CMS repayment has not been quantified in located coverage.
- Quote sites using unadjusted prices show a wider 52-week band than the split/dividend-adjusted series these levels are measured on.
Related · shared themes
OSCR
Oscar Health, Inc.
Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026 close of $32.13 leaves it unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of fiscal 2026 adjusted EPS guidance above $4.80 invalidates the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
ASTH
Astrana Health Inc.
Astrana Health’s full-risk care story depends on meeting Q3 revenue and profit guidance while preserving its raised annual profit outlook. That operational result must arrive before a weekly close below $34 invalidates the recovery thesis.
See also · stocks to watch